Japan-based JCR Pharmaceuticals Co., a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has announced that IZCARGO™ (pabinafusp alfa, or JR-141), a blood-brain barrier-penetrating enzyme replacement therapy (ERT) for Hunter syndrome developed using JCR’s proprietary J-Brain Cargo® technology, received conditional marketing authorisation in Kuwait.
Kuwait is the second market outside Japan where IZCARGO™ has received approval, following the United Arab Emirates in July 2026. IZCARGO™ was approved and launched in Japan in 2021 and is currently being evaluated in an ongoing global Phase III clinical trial.
JCR has been working to expand access to IZCARGO™ outside of Japan while advancing its global clinical development program. As part of this effort, JCR entered into a marketing and distribution agreement with Taiba Middle East FZ LLC and pursued regulatory approval in Kuwait based on the product’s marketing authorization in Japan.
Under this agreement, JCR will also seek marketing authorisation for IZCARGO™ in countries across the Middle East and North Africa (MENA) region, while Taiba will be responsible for sales and distribution in the relevant territories.
